{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=26",
    "query": {
      "intervention": "Formulation #1",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 1757,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T07:19:44.869Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01430533",
      "title": "Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "azelaic acid pre foam formulation",
          "type": "DRUG"
        },
        {
          "name": "Vehicle pre foam formulation",
          "type": "DRUG"
        },
        {
          "name": "Water",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LEO Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 240,
      "start_date": "2011-09",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01430533"
    },
    {
      "nct_id": "NCT02562716",
      "title": "S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Resectable Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation",
          "type": "DRUG"
        },
        {
          "name": "Pancreatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 147,
      "start_date": "2016-01-06",
      "completion_date": "2022-09-26",
      "has_results": true,
      "last_update_posted_date": "2022-10-19",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 807,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 515 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02562716"
    },
    {
      "nct_id": "NCT06628206",
      "title": "Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis (RA)",
        "Psoriatic Arthritis (PsA)"
      ],
      "interventions": [
        {
          "name": "LPX-TI641",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LAPIX Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2024-12-15",
      "completion_date": "2027-02-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 5,
      "location_summary": "Homestead, Florida • South Miami, Florida • Fargo, North Dakota + 2 more",
      "locations": [
        {
          "city": "Homestead",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        },
        {
          "city": "Altoona",
          "state": "Pennsylvania"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06628206"
    },
    {
      "nct_id": "NCT01331239",
      "title": "Safety and Efficacy of LCI699 in Cushing's Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cushings Disease",
        "Cushing Disease"
      ],
      "interventions": [
        {
          "name": "LCI699",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 31,
      "start_date": "2011-03-23",
      "completion_date": "2019-10-22",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01331239"
    },
    {
      "nct_id": "NCT01682902",
      "title": "A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Faster-acting insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2012-09",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682902"
    },
    {
      "nct_id": "NCT03368872",
      "title": "Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sarcopenia"
      ],
      "interventions": [
        {
          "name": "Astaxanthin formulation",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Exercise training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Astavita, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-10",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03368872"
    },
    {
      "nct_id": "NCT00806962",
      "title": "Phase 1 Norwalk Vaccine Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Norovirus"
      ],
      "interventions": [
        {
          "name": "Adjuvant/Excipients",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DEVICE"
        },
        {
          "name": "Norwalk VLP Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "BIOLOGICAL"
      ],
      "sponsor": "LigoCyte Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 61,
      "start_date": "2008-11",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2015-05-06",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00806962"
    },
    {
      "nct_id": "NCT02608229",
      "title": "BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Cancer of Pancreas",
        "Cancer of the Pancreas",
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "BVD-523",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Tumor biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2016-06-06",
      "completion_date": "2020-05-21",
      "has_results": true,
      "last_update_posted_date": "2021-04-21",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02608229"
    },
    {
      "nct_id": "NCT05501327",
      "title": "Dose Regimen Study of SLI-F06 in Healthy Volunteers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scar",
        "Wound Healing"
      ],
      "interventions": [
        {
          "name": "SLI-F06",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scarless Laboratories, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-07-25",
      "completion_date": "2024-10-25",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 2,
      "location_summary": "Encinitas, California • Austin, Texas",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501327"
    },
    {
      "nct_id": "NCT01683266",
      "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "HOE901-U300 (Insulin glargine new formulation)",
          "type": "DRUG"
        },
        {
          "name": "Lantus (Insulin glargine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 549,
      "start_date": "2012-09",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-11-02T07:19:44.869Z",
      "location_count": 82,
      "location_summary": "Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01683266"
    }
  ]
}